Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control

Yam J.; Jiang Yuning; Tang S.; Law Antony K P; Chan J. J.; Wong E.; Ko Simon T. C.; Young A.; Tham C.; Chen L. J.; Pang C.

doi:10.1016/j.ophtha.2018.05.029

← Today's brief

L2 StudySurrogate endpoint

Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control

Yam J. et al. · Ophthalmology · Tuesday, January 1, 2019

Read original

Design Level 2n 438Funding Not reported

The one catch: Surrogate endpoint, not a direct patient outcome.

Source

Yam J. et al.. Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control. Ophthalmology. Tuesday, January 1, 2019.
doi:10.1016/j.ophtha.2018.05.029

Generated, then checked claim-by-claim against the source · how this brief was built →

Physician-designed methodology · Amr Saad, MD MBA

Sign in to rate and bookmark articles

Automated evidence summary, checked against the source. Not medical advice. Verify with the original publication.